HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma

Zhang, Shanyi; Li, Junliang; Xu, Xinke; Zheng, Mingming; Wen, Cheng-cai; Li, Fangcheng

doi:10.1007/s11060-011-0584-7

Cited by 9 publications

(4 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore, upregulation of MHCI is viewed as a therapeutic goal in many types of tumors [29–31]. Similar to plasma, photodynamic therapy uses oxygen radicals and was shown to restore MHCI expression in human glioma [32]. Along similar lines, radiation upregulates MHCI expression in the breast [33], lung [34], and colon cancer [35].…”

Section: Discussionmentioning

confidence: 99%

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma‐Derived Oxidants

Bekeschus

Rödder

Fregin³

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Metastatic melanoma is an aggressive and deadly disease. Therapeutic advance has been achieved by antitumor chemo- and radiotherapy. These modalities involve the generation of reactive oxygen and nitrogen species, affecting cellular viability, migration, and immunogenicity. Such species are also created by cold physical plasma, an ionized gas capable of redox modulating cells and tissues without thermal damage. Cold plasma has been suggested for anticancer therapy. Here, melanoma cell toxicity, motility, and immunogenicity of murine metastatic melanoma cells were investigated following plasma exposure in vitro. Cells were oxidized by plasma, leading to decreased metabolic activity and cell death. Moreover, plasma decelerated melanoma cell growth, viability, and cell cycling. This was accompanied by increased cellular stiffness and upregulation of zonula occludens 1 protein in the cell membrane. Importantly, expression levels of immunogenic cell surface molecules such as major histocompatibility complex I, calreticulin, and melanocortin receptor 1 were significantly increased in response to plasma. Finally, plasma treatment significantly decreased the release of vascular endothelial growth factor, a molecule with importance in angiogenesis. Altogether, these results suggest beneficial toxicity of cold plasma in murine melanomas with a concomitant immunogenicity of potential interest in oncology.

show abstract

Section: Discussionmentioning

confidence: 99%

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma‐Derived Oxidants

Bekeschus

Rödder

Fregin³

et al. 2017

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

show abstract

“…The work of Zhang et al showed that PDT may have this ability. They showed that HMME-PDT enables glioma cells to recover both the expression of functional TAP1 and the presentation of MHC class I surface antigens [202]. However, this is the only report in the field so far, so it needs to be confirmed in other works.…”

Section: Transporter Associated With Antigen Processingmentioning

confidence: 92%

Molecular Insights into Photodynamic Therapy of Glioma

Aebisher,

Woźnicki,

Bartusik-Aebisher

2024

Preprint

View full text Add to dashboard Cite

Cancers, a large and heterogeneous group of malignancies, are becoming an increasingly important cause of premature mortality worldwide. 2% of these are primary CNS tumors, of which 24% are gliomas. These tumors are diverse, but what they have in common is one of the most unfavorable prognoses among all cancers. A patient's future varies depending on the grade of the diagnosed glioma. To date, however, no standard treatment for grade IV has been established. All glioblastomas eventually undergo progression or recurrence. The current standard of treatment, which includes surgical intervention, radiation therapy and chemotherapy, is therefore far from sufficient. Work is constantly underway to discover a new, effective form of glioma therapy. Photodynamic therapy (PDT) may be one of them. It involves the local or systemic application of a photosensitive compound - a photosensitizer (PS), which accumulates in the affected tissues. Photosensitizer molecules absorb light of the appropriate wavelength, initiating activation processes leading to the formation of reactive oxygen species and selective destruction of inappropriate cells. Currently, this method has been approved for the treatment of several cancers. Research focusing on the effective use of PDT in glioma therapy is already underway, with promising results. In our work, we present molecular insights into PDT of glioma. Based on the available literature, we analyze and systematize the impact of various molecules, proteins, transporters and transmitters on the efficacy of PDT and the effect of PDT on their expression. In addition, we highlight gaps in current knowledge and point out directions for future research that may contribute to the efficacy of PDT glioma.

show abstract

“…provided evidence that PDT also induces presentation of surface MHC I related antigens and enhances antigen processing through the restoration of TAP1 protein expression in glioma cells ( 163 ). TAP1 can potentiate the transport of new antigen peptides and therefore is involved in PDT-related immunomodulation ( 163 ). The generation of ROS plays a significant role in PDT-induced immunity ( 160 ).…”

Section: Physical Methods and Their Mechanismsmentioning

confidence: 99%

Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Cancer cells possess specific properties, such as multidrug resistance or unlimited proliferation potential, due to the presence of specific proteins on their cell membranes. The release of proliferation-related proteins from the membrane can evoke a loss of adaptive ability in cancer cells and thus enhance the effects of anticancer therapy. The upregulation of cancer-specific membrane antigens results in a better outcome of immunotherapy. Moreover, cytotoxic T-cells may also become more effective when stimulated ex-vivo toward the anticancer response. Therefore, the modulation of membrane proteins may serve as an interesting attempt in anticancer therapy. The presence of membrane antigens relies on various physical factors such as temperature, exposure to radiation, or drugs. Therefore, changing the tumor microenvironment conditions may lead to cancer cells becoming sensitized to subsequent therapy. This paper focuses on the therapeutic approaches modulating membrane antigens and enzymes in anticancer therapy. It aims to analyze the possible methods for modulating the antigens, such as pharmacological treatment, electric field treatment, photodynamic reaction, treatment with magnetic field or X-ray radiation. Besides, an overview of the effects of chemotherapy and immunotherapy on the immunophenotype of cancer cells is presented. Finally, the authors review the clinical trials that involved the modulation of cell immunophenotype in anticancer therapy.

show abstract

HMME-based PDT restores expression and function of transporter associated with antigen processing 1 (TAP1) and surface presentation of MHC class I antigen in human glioma

Cited by 9 publications

References 51 publications

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma‐Derived Oxidants

Toxicity and Immunogenicity in Murine Melanoma following Exposure to Physical Plasma‐Derived Oxidants

Molecular Insights into Photodynamic Therapy of Glioma

Chemotherapy and Physical Therapeutics Modulate Antigens on Cancer Cells

Contact Info

Product

Resources

About